CA-TIGO
6.4.2022 16:02:05 CEST | Business Wire | Press release
Tigo Energy, Inc. , the solar industry’s leading Flex MLPE (Module Level Power Electronics) supplier, today revealed that one of the Company’s solar systems in the Netherlands consistently produces 30% more energy by using Tigo MLPE Optimizers. The drastic increase in energy production was measured on a per-module basis by the Tigo EI software using the exclusive Reclaimed Energy feature. Solar installers planning to attend Solar Solutions International 2022 in Vijfhuizen are invited to meet with Tigo representatives to discuss hardware and software solutions like those used in this installation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406005028/en/
The 12kWp solar system was designed and installed by homeowner Hans de Git, an energy consultant at NL HDG Energie Advies. The array spans five different roof orientations on the residence in North Holland and combines Tigo TS4-A-O optimizers with a Cloud Connect Advanced (CCA) datalogger and Tigo Access Point (TAP) antennas to enable rapid shutdown, module-level visibility, and Reclaimed Energy optimization. This universal system architecture is powered by Tigo EI software and eliminates the complications of mismatches caused by varied module orientations as well as variations in module output and inverter characteristics. Over the last two years, the system has generated 5MWh of clean energy, of which 1.5MWh represented reclaimed energy provided by the Tigo TS4-A-O optimizers.
“We started using Tigo in 2012, and we have become great fans of the Tigo family of solar MLPE optimizers because they bring benefits to us as the installer and our customers,” said Mr. de Git. “When it came time to choose equipment for a new PV installation on my own house, I didn’t hesitate to choose Tigo again. Because of the specific layout of the array, I would have needed at least five MPPTs to make it work properly, which would have meant adding at least one more inverter. With the Tigo TS4 platform, I avoided the expense of additional inverters, and I can now fully exploit the double MPP tracker of my string inverter.”
“Hearing about the success of Mr. de Git is what the solar industry is all about for me,” said Jaap van Kriekingen, business development manager for Benelux at Tigo Energy. “Tigo EI software provides a clear visual readout of energy production for homeowners, allowing them to see the benefits brought by optimization over time. This level of down-to-the-hour visualization provides the peace of mind that their PV systems are performing at their very best.”
Both Jaap van Kriekingen and Mirko Bindi, Tigo VP EMEA Sales and MD Europe, respectively, will be present at the Solar Solutions International at Expo Haarlemmermeer in Vijfhuizen, the Netherlands, from April 12-14, 2022 at IBC Solar B.V. booth nr B11.1. IBC Solar, which produces tailor-made solutions ranging from small residential PV plants to major solar projects in the Benelux region, will introduce its new AeroFix G3 mounting system at the expo.
To learn more about the Tigo TS4 platform and its exclusive Reclaimed Energy feature, read the latest case study or visit www.tigoenergy.com/ts4 .
About Tigo Energy
Tigo Energy, the worldwide leader in Flex MLPE (Module Level Power Electronics), designs innovative solar power conversion and storage products that provide customers more choice and flexibility. The Tigo TS4 platform increases solar production, decreases operating costs, and enhances safety. When combined with the Tigo Energy Intelligence (EI) platform, it delivers module, system, and fleet-level insights to maximize solar performance and minimize operating costs. The Tigo EI Residential Solar Solution , a flexible solar-plus-storage solution for home installations, rounds out the Company’s portfolio of solar energy technology. Tigo was founded in Silicon Valley in 2007 to accelerate the adoption of solar energy, and its global team supports customers whose systems reliably produce gigawatt-hours of safe solar energy on seven continents. Find us online at www.tigoenergy.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom